[go: up one dir, main page]

USH2251H1 - Method of preparing multiple doses of a pharmaceutical solution from a single-dose - Google Patents

Method of preparing multiple doses of a pharmaceutical solution from a single-dose Download PDF

Info

Publication number
USH2251H1
USH2251H1 US12/453,488 US45348809A USH2251H US H2251 H1 USH2251 H1 US H2251H1 US 45348809 A US45348809 A US 45348809A US H2251 H USH2251 H US H2251H
Authority
US
United States
Prior art keywords
sterile
solution
vial
pharmaceutical solution
syringes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/453,488
Other versions
US20100288393A1 (en
Inventor
Robert A. Malmstrom
Joy L. Meier
Jannet M. Carmichael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
Original Assignee
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs filed Critical US Department of Veterans Affairs
Priority to US12/453,488 priority Critical patent/USH2251H1/en
Assigned to U.S. DEPARTMENT OF VETERANS AFFAIRS reassignment U.S. DEPARTMENT OF VETERANS AFFAIRS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MALMSTROM, ROBERT A., MEIER, JOY L., CARMICHAEL, JANNET M.
Publication of US20100288393A1 publication Critical patent/US20100288393A1/en
Application granted granted Critical
Publication of USH2251H1 publication Critical patent/USH2251H1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/1782—Devices aiding filling of syringes in situ
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics

Definitions

  • the present invention is generally directed to a method of preparing multiple individual doses of a pharmaceutical solution, and more specifically to preparing multiple doses of ranibizumab from a single-dose vial.
  • Opthalmic solution such as ranibizumab is available from the manufacturer in a single-dose vial intended to be used one time per procedure.
  • the drug is supplied with a tuberculin syringe, 30G needle, and a filter needle to extract it from the vial, which contains 0.26 ml of ranibizumab by volume.
  • a significant portion of the drug is unused and wasted.
  • One aspect of the present invention is to provide a method which eliminates or significantly reduces wastage of a pharmaceutical solution, suspension, mixture, composition, or the like in any form (collectively “solution”).
  • Another aspect of the present invention is to provide a method which prepares multiple sterile, stable and effective doses of a pharmaceutical solution from a single-dose.
  • Another aspect of the present invention is to provide a method which prepares multiple sterile, stable and effective doses of an ophthalmic solution from a single-dose.
  • Another aspect of the present invention is to provide a method which prepares multiple doses of ranibizumab from a single-use vial that are sterile, stable and effective for upto three months after refrigeration.
  • the present invention utilizes a sterile procedure to extract multiple 0.5 mg/0.05 ml ranibizumab doses from a singe-use vial that are sterile, stable and effective. The procedure, by minimizing the dead space and decapping the vial, produces multiple doses.
  • Another aspect of the present invention is to provide a method which significantly reduces the cost of treatment for wet age-related macular degeneration (AMD).
  • AMD wet age-related macular degeneration
  • Another aspect of the present invention is to provide a method which provides a retinal specialist or other medical professional with a prefilled syringe with a 31G needle that causes less pain than the manufacturer provided 30G needle.
  • FIG. 1 illustrates the supplies for carrying out a preferred embodiment of the method of the invention
  • FIG. 2 illustrates an uncapping step of the preferred method of the present invention
  • FIG. 3 illustrates an extraction step of the preferred method of the present invention
  • FIG. 4 illustrates placing of the extracted doses into sterile bags for refrigeration and later use
  • FIG. 5 is a bar chart illustrating stability of Lucentis® (raanibizumab) in various samples.
  • FIG. 6 is a bar chart illustrating average ranibizumab concentration after storage at different temperatures and times, showing stability of the split doses for upto three months after refrigeration.
  • the present invention is based, in part, on the discovery that due to the dead space in a syringe, particularly a tuberculin syringe, a significant portion of the drug is unused and wasted.
  • ranibizumab is supplied by the manufacturer in a single-dose vial with a 30G needle and a filter needle.
  • the present invention provides an extraction method which produces multiple doses of ranibizumab from a single-dose vial.
  • the doses produced are sterile, stable and effective for up to three months, less painful to the patient, and easier to use by a retinal specialist.
  • the method described herein is not limited to ranibizumab and can be used for other drugs that have established stability under these condistions such as bevacizumab.
  • Lucentis concentrations were measured using an immunoassay technique as previously described (Ref. 5). Briefly, human recombinant VEGF-165 (R&D Systems, Minneapolis, Minn.) was immobilized on Microlite 2 (Thermo Labsystems, Franklin, Mass.) high-binding plates. The VEGF was diluted to a concentration of 1.0 ⁇ g/mL in a 50 mM carbonate buffer, PH 9, then aliquotted onto the Microlite plates at 100 ⁇ L/well. Following an overnight incubation at 4° C., the plates were washed 3 times with 1X phosphate-buffered saline (PBS) and then blocked for 4 hours at 4° C. with 1% bovine serum albumin in 1X PBS. After 3 washes with 1X PBS, the plates were stored dry at 4° C.
  • PBS 1X phosphate-buffered saline
  • Samples to be assayed for stability were diluted StabilCoat reagent (Surmodics, Inc., Eden Prairie, Minn.) so as to be within the linear range of the assay. Samples were then aliquotted onto a VEGF plate at 100 ⁇ L/well and incubated for 2 hours at room temperature with agitation. For each individual assay, a standard curve was included using ranibizumab of known concentrations. After the initial incubation, the plates were washed 3 times with 1X PBS, 0.05% Tween-20.
  • ranibizumab was detected with a goat anti-hIgG/F(ab′) 2 antibody labeled with horseradish peroxidase (Pierce Biotechnology Inc., Rockford, Ill.) diluted at 1:20,000 in Stabilcoat reagent.
  • the diluted detection antibody was aliquotted onto the VEGF plate at 100 ⁇ L/well and incubated for 45 minutes at room temperature with agitation. Following this incubation, the plate was washed 3 times with 1X PBS. 0.05% Tween-20.
  • the chemiluminescent signal was triggered using the luminol-based SuperSignal ELISA Pico Chemiluminescent Substrate (Pierce Biotechnology Inc.) according to the manufacturer's instructions.
  • VISN (Veterans Integrated Service Network) 21 Cost Impact Estimate Based on Current Use days days Vials if w/2-4 w/>4 Vials Potential appt is Add'l $ Tot $ Site Pts Doses Cost doses doses Avoid $ Avoid ⁇ 1 day Avoid Avoid VANC 46 121 $177K 25 6 63 $92K 13 $19K $111K VAPA 27 73 $107K 15 5 34 $50K 6 $9K $58K VASF 15 34 $50K 4 0 5 $7K 7 $10K $18K 6 Mon 88 228 $333K 44 11 102 $149K 26 $38K $187K Total 1 Yr 176 456 $666K 88 22 204 $298K 52 $76K $374K Total
  • Table 5 corresponds to FIG. 6 and provides stability data for ranibizumab in various samples over a six-month period.
  • Tables 7 and 8 correspond to FIG. 5 and provide data for average ranibizumab concentration after storage at different temperatures and times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A method of preparing multiple doses of a pharmaceutical solution, such as ranibizumab, from a single-dose container, includes providing a sterile enclosed area with a plurality of unused sterile syringes, a decapper, and a plurality of sterile bags, opening a single-use container of a pharmaceutical solution in the enclosed area, withdrawing a first portion of the pharmaceutical solution using one of the sterile syringes, withdrawing a second portion of the pharmaceutical solution using a second of the sterile syringes, repeating the previous step for the remaining pharmaceutical solution using the remaining sterile syringes, and placing the sterile syringes containing portions of the pharmaceutical solution individually in the sterile bags.

Description

FIELD AND BACKGROUND OF THE INVENTION
The present invention is generally directed to a method of preparing multiple individual doses of a pharmaceutical solution, and more specifically to preparing multiple doses of ranibizumab from a single-dose vial.
Opthalmic solution, such as ranibizumab is available from the manufacturer in a single-dose vial intended to be used one time per procedure. The drug is supplied with a tuberculin syringe, 30G needle, and a filter needle to extract it from the vial, which contains 0.26 ml of ranibizumab by volume. However, due to the dead space in the tuberculin syringe, a significant portion of the drug is unused and wasted.
ASPECTS OF THE INVENTION
The present disclosure is directed to various aspects of the present invention.
One aspect of the present invention is to provide a method which eliminates or significantly reduces wastage of a pharmaceutical solution, suspension, mixture, composition, or the like in any form (collectively “solution”).
Another aspect of the present invention is to provide a method which prepares multiple sterile, stable and effective doses of a pharmaceutical solution from a single-dose.
Another aspect of the present invention is to provide a method which prepares multiple sterile, stable and effective doses of an ophthalmic solution from a single-dose.
Another aspect of the present invention is to provide a method which prepares multiple doses of ranibizumab from a single-use vial that are sterile, stable and effective for upto three months after refrigeration. In particular, the present invention utilizes a sterile procedure to extract multiple 0.5 mg/0.05 ml ranibizumab doses from a singe-use vial that are sterile, stable and effective. The procedure, by minimizing the dead space and decapping the vial, produces multiple doses.
Another aspect of the present invention is to provide a method which significantly reduces the cost of treatment for wet age-related macular degeneration (AMD).
Another aspect of the present invention is to provide a method which provides a retinal specialist or other medical professional with a prefilled syringe with a 31G needle that causes less pain than the manufacturer provided 30G needle.
BRIEF DESCRIPTION OF THE DRAWINGS
One of the above and other aspects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) invention, as illustrated in the drawings, in which:
FIG. 1 illustrates the supplies for carrying out a preferred embodiment of the method of the invention;
FIG. 2 illustrates an uncapping step of the preferred method of the present invention;
FIG. 3 illustrates an extraction step of the preferred method of the present invention;
FIG. 4 illustrates placing of the extracted doses into sterile bags for refrigeration and later use;
FIG. 5 is a bar chart illustrating stability of Lucentis® (raanibizumab) in various samples; and
FIG. 6 is a bar chart illustrating average ranibizumab concentration after storage at different temperatures and times, showing stability of the split doses for upto three months after refrigeration.
 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT(S) OF THE INVENTION
The present invention is based, in part, on the discovery that due to the dead space in a syringe, particularly a tuberculin syringe, a significant portion of the drug is unused and wasted. In particular, the present inventors discovered that ranibizumab is supplied by the manufacturer in a single-dose vial with a 30G needle and a filter needle. However, due to the dead space, much of the drug is not used is therefore wasted. The present invention provides an extraction method which produces multiple doses of ranibizumab from a single-dose vial. The doses produced are sterile, stable and effective for up to three months, less painful to the patient, and easier to use by a retinal specialist. The method described herein is not limited to ranibizumab and can be used for other drugs that have established stability under these condistions such as bevacizumab.
The following is a preferred embodiment for carrying out the method of the present invention.
Supply List (FIG. 1).
    • Sterile field (18″×26″) by Busse Ref No. 696.
    • Sterile surgical gloves —one pair for the preparer and one for the assistant.
    • Four unopened, individually contained, sterile Monoject 0.3 ml 31 G 5/16 inch insulin syringes per vial of ranibizumab. NDC 08881609331; McK #1980101.
    • One vial of ranibizumab.
    • One 13 mm, or 13 mm/20 mm dual action vial decapper —available from Health Care Logistics item #7773.
    • Four sterile Whirl-Pak plastic bags per vial of ranibizumab. Bags may be obtained from Taylor Scientific (314) 962-5555; item #10-1695-06.
    • Sterile forceps.
    • Sterile hemostat.
    • Laminar or vertical airflow hood.
Sterile Field and Setup
    • 1. Aseptically prepare area according to USP 797 procedures in a clean laminar or vertical airflow hood.
    • 2. Preparer and assistant wash hands.
    • 3. Preparer applies sterile gloves using sterile technique.
    • 4. Assistant opens sterile field package for preparer, who places it in laminar hood without contaminating gloves.
    • 5. Assistant opens each sterile insulin syringe onto sterile field using sterile technique.
    • 6. Assistant removes plastic cap of ranibizumab.
    • 7. After properly applying alcohol to ranibizumab vial, the assistant removes metal top with decapper without removing the rubber stopper (FIG. 2).
    • 8. Assistant rewashes hands, and applies sterile gloves inside hood.
Dose Extraction (FIG. 3).
    • 1. Assistant removes rubber top of ranibizumab vial using sterile forceps without contaminating top of vial.
    • 2. Assistant holds uncapped ranibizumab vial steady, while preparer inserts the insulin syringe needle inside without touching any part of the needle to the outside of the vial. In order to prevent dulling, it is important not to touch the needle to the bottom of the glass vial. If the needle touches anything but the drug inside vial, discard syringe and use another syringe.
    • 3. Preparer withdraws ranibizumab to the 0.05 ml (5 unit) mark of the U-100 insulin syringe.
    • 4. Preparer caps the insulin syringe and sets aside.
    • 5. Repeat steps 2 to 4 to get the second, third and fourth doses.
    • 6. If a bubble is visible, invert the syringe with the needle pointing upwards, tap the syringe gently until the bubble rises to the top, pull back the plunger slightly and push upwards until the bubbles disappear and the needle is primed.
    • 7. Assistant opens sterile plastic bag and preparer places each syringe inside with needle facing down (FIG. 4). Assistant seals the plastic bag and removes from the hood.
    • 8. Assistant affixes patient label to each bag with 60 day expiration date from time of preparation.
Sterility Testing
    • 1. Draw remaining volume in vial into syringe and test for sterility using tryptic soy agar plates.
    • 2. Disperse the drug onto the culture medium by spreading the sample over the agar surface by tilting and rotating the plate. Do not streak the plate.
    • 3. Air dry plate until the liquid has evaporated.
    • 4. Send inoculated plates to laboratory.
Stability Testing
    • 1. Dilute assays with StabilCoat reagent.
    • 2. Detect bound ranibizumab with goat anti-hIgG/F(ab′) 2 antibody labeled with horseradish peroxidase.
    • 3. Aliquot diluted detection antibody onto the VEGF plate at 100 μL/well, incubate and agitate.
    • 4. Trigger chemiluminescent signal using the luminol-based SuperSignal ELISA Pic substrate.
    • 5. The assay was performed by the Mayo Clinic College of Medicine, Clinical Immunology Laboratory, Rochester, Minn.
      Lucentis Immunoassay Protocol
Lucentis concentrations were measured using an immunoassay technique as previously described (Ref. 5). Briefly, human recombinant VEGF-165 (R&D Systems, Minneapolis, Minn.) was immobilized on Microlite 2 (Thermo Labsystems, Franklin, Mass.) high-binding plates. The VEGF was diluted to a concentration of 1.0 μg/mL in a 50 mM carbonate buffer, PH 9, then aliquotted onto the Microlite plates at 100 μL/well. Following an overnight incubation at 4° C., the plates were washed 3 times with 1X phosphate-buffered saline (PBS) and then blocked for 4 hours at 4° C. with 1% bovine serum albumin in 1X PBS. After 3 washes with 1X PBS, the plates were stored dry at 4° C.
Samples to be assayed for stability were diluted StabilCoat reagent (Surmodics, Inc., Eden Prairie, Minn.) so as to be within the linear range of the assay. Samples were then aliquotted onto a VEGF plate at 100 μL/well and incubated for 2 hours at room temperature with agitation. For each individual assay, a standard curve was included using ranibizumab of known concentrations. After the initial incubation, the plates were washed 3 times with 1X PBS, 0.05% Tween-20. The bound ranibizumab was detected with a goat anti-hIgG/F(ab′)2 antibody labeled with horseradish peroxidase (Pierce Biotechnology Inc., Rockford, Ill.) diluted at 1:20,000 in Stabilcoat reagent. The diluted detection antibody was aliquotted onto the VEGF plate at 100 μL/well and incubated for 45 minutes at room temperature with agitation. Following this incubation, the plate was washed 3 times with 1X PBS. 0.05% Tween-20. The chemiluminescent signal was triggered using the luminol-based SuperSignal ELISA Pico Chemiluminescent Substrate (Pierce Biotechnology Inc.) according to the manufacturer's instructions.
Sterility in Syringe
      • Testing for bacterial growth at 37° C. in 73 syringes over a period of 1 to 60 days demonstrated sterility. No bacterial growth was detected.
        Stability in Syringe
Multiple dose extraction or splitting from a single-use ranibizumab vial into syringes was found to be safe and the doses stable for upto three months under refrigeration (see FIG. 5 and Tables 5 & 7 ).
TABLE 1
Similar Drug Cost Comparison Estimate
Price/dispense Cost/
Drug unit Dose dose Cost/Year/Pt
Ranibizumab $1,450 per vial 0.5 mg $1,450 $17,400
(Lucentis ®, (1 dose/vial) intravitreally
Genentech, Inc.) every 4
weeks
Pegaptanib* $760 per 0.3 mg   $507  $6,080
(Macugen ®, syringe intravitreally
Pfizer, Inc.) (1 dose/syr) every 6
weeks
Bevacizumabl $391 per vial 1.25 mg $25-400 $300-$4,800
(Avastin ® (˜25 doses per intravitreally
Genentech, Inc.) vial)* every 4
weeks
TABLE 2
Total VISN (Veterans Integrated Service Network)
21 Drug Cost Estimate (n = 572 pts)
Drug and Dose Treat 20% × 1 yr Treat 50% × 1 yr Treat 90% × 1 yr
Ranibizumab $8,700 × 114 $8,700 × 286 $8,700 × 515
0.3 mg Q4wk pts = $995,280 pts = $2,488,200 pts = $4,480,500
$725/dose
Ranibizumab $17,400 × 114 $17,400 × 286 $17,400 × 515
0.5 mg Q4wk pts = $1,990,560 pts = $4,976,400 pts = $8,961,000
$1,450/dose
Ranibizumab $5,075 × 114 $5,075 × 286 $5,075 × 515
0.3 mg month- pts = $580,580 pts = $1,451,450 pts = $2,613,625
ly × then Q3
months, 7
doses/yr @
$725/dose
Pegaptanib $6,080 × 114 $6,080 × 286 $6,080 × 515
0.3 mg Q6wk pts = $695,552 pts = $1,738,880 pts = $3,131,200
$507/dose
Bevacizumab $300-$4,800 × $300-$4,800 × $300-$4,800 ×
1.25 mg Q4wk 114 = $34,320- 286 = $85,800- 515 = $154,500-
$25-$400/dose $549,120 $1,372,800 $2,472,000
TABLE 3
VISN (Veterans Integrated Service Network)
21 Cost Impact Estimate Based on Current Use
days days Vials if
w/2-4 w/>4 Vials Potential appt is Add'l $ Tot $
Site Pts Doses Cost doses doses Avoid $ Avoid ±1 day Avoid Avoid
VANC 46 121 $177K 25 6 63  $92K 13 $19K $111K
VAPA 27 73 $107K 15 5 34  $50K 6  $9K  $58K
VASF 15 34  $50K 4 0 5  $7K 7 $10K  $18K
6 Mon 88 228 $333K 44 11 102 $149K 26 $38K $187K
Total
1 Yr 176 456 $666K 88 22 204 $298K 52 $76K $374K
Total
COST SAVINGS
TABLE 4A
$405,000 REAL VETERANS AFFAIRS SAVINGS
(May 01, 2007 to Jul. 31, 2008)
Ranibizumab #Eyes # Treated Veterans
Lucentis ® 0.5 mg #Doses Treated Patients Contract Cost
Standard 389 105 96 $540,000
Technique
Splitting 389 105 96 $135,000
Technique
TABLE 4B
$6.59 BILLION ESTIMATED SAVINGS PER YEAR
Ranibizumab Treat 10% Treat 25% Treat 75%
(Lucentis ®) 0.5 mg Cost2 (Billion) Cost2 (Billion) Cost2 (Billion)
Standard $1.17 $2.93 $8.78
Technique
$9750/pt/yr
Splitting $0.30 $0.74 $2.19
Technique
$2438/pt/yr
Cost Savings/yr $0.87 $2.19 $6.59
Estimated U.S.A. Drug Costs: n = 1.2 million patients with neovascular AMD1 each receiving 4 doses/year.
1The Eye Diseases Prevalence Research Group Arch Ophthalmol. 2004; 122:564-572.
2Average Wholesale Price of Ranibizumab is $2438 per vial.
The following Table 5 corresponds to FIG. 6 and provides stability data for ranibizumab in various samples over a six-month period.
TABLE 5
Average
Concentration
(mg/mL) SD
Week 1 Week #1, Sample 8.65 1.73 avg wk 1 (syr)
#1, Sep. 26, 2007 8.53 +/− 1.17
Week #1, Sample 8.15 1.03
#1, Sep. 27, 2007
Week #1, Sample 8.93 0.90
#2, Sep. 26, 2007
Week #1, Sample 8.39 1.03
#2, Sep. 27, 2007
Week 3 Week #3, Sample 9.62 0.76 Avg wk 3 (syr)
#1, Sep. 26, 2007 8.68 +/− 0.89
Week #3, Sample 7.93 0.84
#1, Sep. 27, 2007
Week #3, Sample 8.88 1.04
#2, Sep. 26, 2007
Week #3, Sample 8.29 0.90
#2, Sep. 27, 2007
Week 4 Week #4, Sample 8.65 0.61 Avg wk 4 (syr)
#1, Sep. 26, 2007 8.14 +/− 0.96
Week #4, Sample 7.30 1.10
#1, Sep. 27, 2007
Week #4, Sample 8.89 0.97
#2, Sep. 26, 2007
Week #4, Sample 7.71 1.14
#2, Sep. 27, 2007
Vial #1, 8.87 0.39 Avg 4 wk (vial)
Sep. 26, 2007 8.45 +/− 0.43
Vial #1, 8.02 0.47
Sep. 27, 2007
Vial #2, 8.50 0.89 Avg 1 wk (vial)
Sep. 26, 2007 7.89 +/− 0.9 
Vial #2, 7.27 0.91
Sep. 27, 2007
Unopened vial, 8.01 0.71 8.9%
Feb. 27, 2008
Unopened vial, 8.11 1.19 14.7%
Feb. 28, 2008
Month 2 Refrigerated 7.89 0.86 10.9%
syringe,
Feb. 27, 2008
Refrigerated 7.47 0.35 4.7%
syringe,
Feb. 28, 2008
Month 3 Refrigerated 6.89 0.75 10.9%
syringe #1,
Feb. 27, 2008
Refrigerated 8.52 0.85 10.0%
syringe #1,
Feb. 28, 2008
Refrigerated 8.06 1.12 13.9%
syringe #2,
Feb. 27, 2008
Refrigerated 7.85 2.13 27.1%
syringe #2
Feb. 28, 2008
Refrigerated vial, 6.27 1.27 20.3%
Feb. 27, 2008
Refrigerated vial, 6.46 1.44 22.3%
Feb. 28, 2008
Frozen syringe 4.97 0.47 9.5%
#1, Feb. 27, 2008
Frozen syringe 6.07 0.87 14.3%
#1, Feb. 28, 2008
Frozen syringe 5.87 0.93 15.8%
#2, Feb. 27, 2008
Frozen syringe 5.78 0.94 16.3%
#2, Feb. 28, 2008
Month 6 Refrigerated vial, 7.02 0.71 10.1%
Feb. 27, 2008
Refrigerated vial, 7.47 1.19 15.9%
Feb. 28, 2008
Frozen syringe 4.30 0.31 7.2%
#1, Feb. 27, 2008
Frozen syringe 4.76 0.51 10.7%
#1, Feb. 28, 2008
Frozen syringe 3.82 0.37 9.7%
#2, Feb. 27, 2008
Frozen syringe 2.72 0.63 23.2%
#2, Feb. 28, 2008
The following Tables 7 and 8 correspond to FIG. 5 and provide data for average ranibizumab concentration after storage at different temperatures and times.
TABLE 7
Average Concentration
(mg/mL) SD
Unopened vial @4° C. 8.06 0.95
7 days @4° C. 8.53 1.17
20 days @4° C. 8.68 0.89
28 days @4° C. 8.14 0.96
67 days @4° C. 7.89 0.86
91 days @4° C. 7.83 1.21
196 days @4° C. 7.25 0.95
91 days @−10° C. 5.67 0.80
196 days @−10° C. 3.90 0.46
TABLE 8
Statistics (t-test)
Storage Time & Temperature P Value
7 days @ 4° C. 0.210
20 days @ 4° C. 0.277
28 days @ 4° C. 0.899
67 days @ 4° C. 0.151
91 days @ 4° C. 0.382
196 days @ 4° C. 0.032
91 days @ −10° C. <0.001
196 days @ −10° C. <0.001
TABLE 9
Adverse Reactions
0 CASES OF ENDOPHTHALMITIS
Increased Increased Abrasion/ Total #
BP IOP Irritation Other ADR
1 (0.3%) 1 (0.3%) 5 (1.3%) 2 (0.5%) 9 (2.3%)
Reported May 1, 2007 to Jul. 31, 2008.
(n = 96 pts; 105 eyes; 389 injections).
Summary of main advantages of the present invention.
    • Using vial decapping technique and taking advantage of reduced syringe dead-space with 31 G, 5/16 inch needles, consistently produces 4 doses per vial.
    • Syringe sterility testing on each batch found no bacterial growth.
    • Ranibizumab was found to be stable in syringes for up to 3 months at 4° C.
    • No serious complications were found in 389 doses.
    • Incidence of minor adverse reactions was 2.3% which is similar to that seen with standard injection technique.
Conclusion
    • Multiple dose extraction from ranibizumab vials into syringes is safe and the product is stable.
    • Drug costs are reduced by 75% .
    • Minimal drug wastage since ranibizumab stable in syringes for up to 3 months under refrigeration.
    • Smaller gauge needle and shorter needle length make ranibizumab injection more comfortable for the patient and easier for the surgeon.
While this invention has been described as having preferred sequences, ranges, steps, materials, structures, features, and/or designs, it is understood that it is capable of further modifications, uses and/or adaptations of the invention following in general the principle of the invention, and including such departures from the present disclosure as those come within the known or customary practice in the art to which the invention pertains, and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.
REFERENCES
The following references, including any cited in the disclosure herein, are hereby incorporated herein in their entirety by reference.
    • 1. USP Chapter 797 Pharmaceutical Compounding: Sterile Preparations.
    • 2. VISN 21, Aseptic Ranibizumab (Lucentis®) Dose Preparation Procedure.
    • 3 . VISN 21 Criteria for non-formulary use of ranibizumab injection.
    • 4. National PBM Drug Monograph for Ranibizumab (Lucentis®).
    • 5. Bakri S J, Snyder M R, Reid J M, Pulido J S Ezzat M K, Singh R J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology, 114 (2007) 2179-2182.

Claims (17)

What is claimed is:
1. A method of preparing a plurality of doses of a pharmaceutical solution from a single-dose container, comprising the steps of:
a) providing a sterile enclosed area with a plurality of unused sterile syringes, a decapper, and a plurality of sterile bags;
b) opening a single-use container of a pharmaceutical solution in the enclosed area;
c) withdrawing a first portion of the pharmaceutical solution using one of the sterile syringes;
d) withdrawing a second portion of the pharmaceutical solution using a second of the sterile syringes;
e) repeating step d) for the remaining pharmaceutical solution using the remaining sterile syringes; and
f) placing the sterile syringes containing portions of the pharmaceutical solution individually in the sterile bags.
2. The method of claim 1, wherein:
steps c) and d) are performed while the single-use container is held steady.
3. The method of claim 1, wherein:
steps c) and d) are performed by one person while the single-use container is held steady by another person.
4. The method of claim 2, wherein:
steps c) and d) are performed without contacting the container with the syringe needle.
5. The method of claim 1, wherein;
step c) comprises withdrawing 0.05 ml of the pharmaceutical solution.
6. The method of claim 1, wherein:
step c) or d) comprises withdrawing a supplemental portion of the pharmaceutical solution if a bubble appears in the withdrawn solution.
7. The method of claim 6, wherein:
step c) and d) comprise withdrawing 0.05 ml of the pharmaceutical solution.
8. The method of claim 7, wherein:
the supplemental portion comprises withdrawing 0.005 ml of the pharmaceutical solution.
9. The method of claim 1, wherein:
the pharmaceutical solution comprises about 0.26 ml of an ophthalmic drug provided in a vial.
10. The method of claim 9, wherein:
the drug comprises ranibizumab.
11. The method of claim 9, wherein:
the method prepares four individual doses of about 0.05 ml each of the ophthalmic drug.
12. The method of claim 1, wherein:
the sterile enclosed area comprises a laminar or vertical airflow hood.
13. A method of preparing a plurality of individual doses of an ophthalmic solution from a single-dose vial, comprising the steps of:
a) providing a sterile enclosed hood with a plurality of unused sterile syringes, a vial decapper, and a plurality of sterile bags;
b) opening a single-use vial containing about 0.26 ml of an ophthalmic solution in the hood;
c) withdrawing about 0.05 ml of the ophthalmic solution using one of the sterile syringes;
d) withdrawing about 0.05 ml of the ophthalmic solution using a second of the sterile syringes;
e) repeating step d) for the remaining ophthalmic solution using the remaining syringes; and
f) placing the sterile syringes each containing about 0.05 ml of the ophthalmic solution individually in the sterile bags.
14. The method of claim 13, wherein:
steps c) and d) comprise withdrawing an additional 0.005 ml of the ophthalmic solution if a bubble appears in the withdrawn solution.
15. The method of claim 13, wherein:
steps c) and d) are performed without contacting the vial with the syringes needle.
16. The method of claim 13, wherein:
the ophthalmic solution comprises ranibizumab.
17. The method of claim 16, wherein:
the method prepares four individual doses of about 0.05 ml each of ranibizumab solution.
US12/453,488 2009-05-12 2009-05-12 Method of preparing multiple doses of a pharmaceutical solution from a single-dose Abandoned USH2251H1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/453,488 USH2251H1 (en) 2009-05-12 2009-05-12 Method of preparing multiple doses of a pharmaceutical solution from a single-dose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/453,488 USH2251H1 (en) 2009-05-12 2009-05-12 Method of preparing multiple doses of a pharmaceutical solution from a single-dose

Publications (2)

Publication Number Publication Date
US20100288393A1 US20100288393A1 (en) 2010-11-18
USH2251H1 true USH2251H1 (en) 2011-01-04

Family

ID=43067549

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/453,488 Abandoned USH2251H1 (en) 2009-05-12 2009-05-12 Method of preparing multiple doses of a pharmaceutical solution from a single-dose

Country Status (1)

Country Link
US (1) USH2251H1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3858405T (en) 2012-06-01 2023-06-26 Novartis Ag Syringe
US20180092770A1 (en) * 2016-03-14 2018-04-05 Virchow Biotech Pvt. Ltd. Sterile protective cover comprising a device for opthalmic delivery
EP3773800A1 (en) * 2018-04-09 2021-02-17 SiO2 Medical Products, Inc. Stretchable plunger assemblies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6073759A (en) * 1997-04-10 2000-06-13 Johns Hopkins University Pre-filled package containing unit dose of medical gas and method of making same
US7744580B2 (en) * 2003-02-05 2010-06-29 Arcadophta Device and procedure for the extemporaneous preparation of an individual quantity of sterile liquid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6073759A (en) * 1997-04-10 2000-06-13 Johns Hopkins University Pre-filled package containing unit dose of medical gas and method of making same
US6494314B1 (en) * 1997-04-10 2002-12-17 Johns Hopkins University Pre-filled package containing unit dose of medical gas and method of making same
US7744580B2 (en) * 2003-02-05 2010-06-29 Arcadophta Device and procedure for the extemporaneous preparation of an individual quantity of sterile liquid

Also Published As

Publication number Publication date
US20100288393A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
Schargus et al. Issues with intravitreal administration of anti-VEGF drugs
Goldberg et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results
AU2019265005A1 (en) High concentration vegf receptor fusion protein containing formulations
Khan et al. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial
Ricci et al. In-use physicochemical and microbiological stability of biological parenteral products
EP3624829A1 (en) Octreotide injection
USH2251H1 (en) Method of preparing multiple doses of a pharmaceutical solution from a single-dose
Thomas Intramuscular injections for COVID-19 vaccinations
Wani et al. Incidence of endophthalmitis after intravitreal bevacizumab using aliquots prepared on-site in 2 operating rooms in Kuwait
Ludwig Parenteral dosage forms: introduction and historical perspective
Fuentes-Irigoyen et al. Consensus SEO-SEFH of recommendations for use and compounding of ophthalmic preparations
Peterson et al. Long-term physical stability, sterility, and anti-VEGF bioactivity of repackaged bevacizumab in 2-mL glass vials
Ringwald et al. Travel and oral anticoagulation
Romero-Aroca et al. Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
Lanzetta et al. Intravitreal injections: a healthcare failure modes and effects analysis
Neamah et al. Assessment of the Microbial Contamination Rate of Multi-puncture Vials of Bevacizumab and the Risk of Endophthalmitis
Barakat et al. Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe
Nelson et al. Allergen immunotherapy extract preparation manual
US20250034280A1 (en) Method and apparatus for using omalizumab
Semes et al. Evaluation of the Xal-Ease™ latanoprost delivery system
US20250255937A1 (en) Pre-filled manual injector apparatus
Fuentes-Irigoyen HOSPITALARIA
WO2025233684A1 (en) Subcutaneous formulations, pre-filled syringes and methods of use thereof
Allmendinger et al. Intravitreal Injections–More Than Meets the Eye: a Technical View of Product Use
Fuentes-Irigoyen et al. Consensus SEO-SEFH of recommendations for use and compounding of ophthalmic preparations Consenso SEO-SEFH sobre recomendaciones de utilización y elaboración de preparaciones oftálmicas

Legal Events

Date Code Title Description
AS Assignment

Owner name: U.S. DEPARTMENT OF VETERANS AFFAIRS, DISTRICT OF C

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MALMSTROM, ROBERT A.;MEIER, JOY L.;CARMICHAEL, JANNET M.;SIGNING DATES FROM 20090427 TO 20090504;REEL/FRAME:022705/0572

STCF Information on status: patent grant

Free format text: PATENTED CASE